Efficacy and safety of AEB071 in combination with mycophenolate acid sodium, basiliximab and steroids in preventing acute rejection after kidney transplantation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
124
Efficacy will be defined using a composite efficacy failure end point (treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up) between treatment and control arms
Renal function assessed by calculated and measured glomerular filtration rate (GFR). Incidence of Chronic Allograft Nephropathy using biopsies
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
USC Medical Center
Los Angeles, California, United States
University of California San Diego
San Diego, California, United States
California Pacific Medical Center
San Francisco, California, United States
UCSF
San Francisco, California, United States
University of Colorado Health Science Center
Denver, Colorado, United States
Lifelink, Inc.
Tampa, Florida, United States
U of Maryland Medical Center
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
University of Michigan Health System
Ann Arbor, Michigan, United States
...and 31 more locations